COMBINING TO CURE®

Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer.

INVESTOR PRESENTATION

October 28, 2025

ARCUS BIOSCIENCES

Forward-Looking Statements/Safe Harbor

Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in this presentation are forward-looking statements, including statements about: our strategy; the potential, advantages, and commercial opportunity of our investigational products; expectation that our cash, investments and facilities are sufficient to fund operations through our initial pivotal read-outs for domvanalimab, quemliclustat and casdatifan, which includes PEAK-1; anticipated benefits of our collaborations with Gilead, Taiho and AstraZeneca; and the timing of clinical and developmental milestones, including the timing of data readouts and data presentations.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those contained in any forward-looking statements we may make, including, but not limited to: risks associated with preliminary or interim clinical data or preclinical data not being guarantees that future data will be similar; the unexpected emergence of adverse events or other undesirable side effects; difficulties or delays in initiating, conducting or completing our clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials; unfavorable global economic, political and trade conditions which may increase the cost of our activities or exacerbate the other risks described herein; our dependence on Gilead for the successful development and commercialization of investigational products they've optioned; difficulties associated with the management of collaboration activities; changes in the competitive landscape; our limited operating history and our ability to manage our growth; our ability to obtain and maintain intellectual property protection for our product candidates; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those anticipated or implied in the forward-looking statements. Further information on these and other factors that could affect the forward-looking statements made herein are described in our most recent periodic reports filed with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

Third-Party Sources: This presentation contains certain information related to or based on studies, publications, surveys and other data obtained from third-party sources, and our own internal estimates and research, including without limitation relating to market size and potential. This information is based on a number of assumptions, projections and estimates, including with respect to our future performance and the future performance of markets in which we operate, and are necessarily subject to a high degree of uncertainty and risk and you are cautioned not to give undue weight to such estimates.

No Regulatory Approval: All of Arcus's molecules are investigational and Arcus (and Gilead for all of the molecules in each optioned program) has not received approval from any regulatory authority for any use globally, nor established the safety and efficacy of these investigational molecules.

Notice of Trademark: The Arcus name and logo are the property of Arcus. All other trademarks used herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of Arcus.

Arcus is Well-Capitalized to Advance its Broad Portfolio of Late-Stage Programs Through Phase 3 Readouts

CASDATIFAN: COMMERCIALLY-VALIDATED MECHANISM

PEAK-1
Phase 3 in 2L ccRCC

ARC-20
Phase 1b in late- and early-line ccRCC

eVOLVE RCC02
Phase 1b/3 in 1L ccRCC

DOMVANALIMAB: APPROACHING PHASE 3 DATA

STAR-221
1L Gastric
Ph 3 Data expected in 2026

STAR-121
1L NSCLC
(PD-L1 all comer)

PACIFIC-8
Stage 3 NSCLC

QUEMLICLUSTAT: PHASE 3 FULLY ENROLLED

PRISM-1 1L Pancreatic

EMERGING I&I PORTFOLIO

Multiple active research programs; FIH study for MRGPRX2 inhibitor planned for 2026

$841 MILLION IN CASH*

Funded through initial pivotal readouts for dom, quemli and cas, **including PEAK-1****

* cash, cash equivalents and marketable securities as of September 30, 2025

** runway estimate based on cash, cash equivalents, marketable securities, available facilities, and current planned operations

1L: first-line; 2L: second-line; cabo: cabozantinib; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; dom: domvanalimab; FIH: first in human; I&I: immunology and inflammation; NSCLC: non-small cell lung cancer; PD-L1: programmed cell death ligand 1; SM: small molecule; quemli: quemliclustat; R&D: research & development

ARCUS BIOSCIENCES

Multiple Registrational Programs Targeting Substantial Market Opportunities and Unmet Medical Need

	TRIAL NAME	INDICATION	PATIENTS (MAJOR MARKETS[1])	MARKET POTENTIAL (MAJOR MARKETS[2])	COMMERCIAL RIGHTS
CAS HIF-2α small molecule inhibitor	PEAK-1	Post-IO ccRCC	19K	~$2B	Arcus
	eVOLVE RCC02	IO-naive ccRCC	21K	~$3B	
DOM (+ ZIM) Fc-silent anti-TIGIT mAb + anti-PD-1 mAb	STAR-221	1L Gastric/GEJ/EAC – all comers	105K	~$3B	Arcus / Gilead
	STAR-121	1L NSCLC – all comers	307K	~$10B	
	PACIFIC-8	Stage 3 NSCLC, PD-L1>1%	35K[3]	~$2B	
QUEMLI Small molecule CD73 inhibitor	PRISM-1	1L PDAC	109K	>$4B	Arcus / Gilead

1. Drug Treatable Addressable Populations (Major Markets) in 2024; Decision Resources Group
2. Major Markets (US, EU5, JP) - total projected 2034 PD-(L)1 + TIGIT opportunity, quemli opportunity & HIF-2α opportunity
3. cCRT responding patients

1L: first-line; B: billion; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; dom: domvanalimab; EAC: esophageal adenocarcinoma; GEJ: gastroesophageal junction; IO: immunotherapy; mAb: monoclonal antibody; NSCLC: non-small cell lung cancer; PD-L1: programmed death-ligand 1; PDAC: pancreatic ductal adenocarcinoma; quemli: quemliclustat; zim: zimberelimab

Several Positive Updates in Just the Last Month

IMPRESSIVE CASDATIFAN DATA PRESENTED AT INVESTOR EVENT

- **31% cORR and 12.2 months PFS** in a pooled analysis of all four monotherapy cohorts in late-line ccRCC (n=121)
- **35% cORR and PFS was not reached with 12+ months median follow-up** in the 100mg QD tablet cohort (going forward dose and formulation)
- In biomarker analysis, the data demonstrated that **greater EPO suppression is associated with better clinical activity of cas**

TAIHO OPT IN TO CASDATIFAN

- **Taiho exercised their option to casdatifan** for Japan and Asia (ex-China)
- **Further validates the casdatifan data and brings in additional capital** (via upfront payment + milestones) and additional support for cas development

FIRST DISCLOSURE OF I&I PROGRAMS

- Arcus has had a 2+ year discovery effort focused on I&I which has now yielded **5 active programs**
- The most advanced programs: small molecules against MRGPRX2 and TNFα; **Initiation of first-in-human study for MRGPRX2 expected in 2026**

EDGE-GASTRIC ORAL PRESENTATION AT ESMO

- **26.7 months OS was reported for dom + zim + chemo in 1L GI adenocarcinomas (ITT population)** in Cohort A1 of the EDGE-Gastric study
- Results were simultaneously published in Nature Medicine

1L: first-line; cabo: cabozantinib; cas: casdatifan, ccRCC: clear cell renal cell carcinoma; dom: domvanalimab; EPO: erythropoietin; ESMO: European Society for Medical Oncology; GI: gastrointestinal; mPFS: median progression-free survival; ORR: overall response rate; OS: overall survival; zim: zimberelimab

ARCUS BIOSCIENCES

Multiple Upcoming Potential Catalysts

TIMING	STUDY	PRODUCT	EVENT
Early 2026	ARC-20	Casdatifan	• Additional analysis of the cas monotherapy cohorts in late-line ccRCC
Mid-2026	ARC-20	Casdatifan	• ORR and PFS data from the cas + cabo cohort in IO-experienced ccRCC
2026	Phase 1	MRGPRX2	• Initiation of first-in-human study
2H 2026	ARC-20 eVOLVE RCC02	Casdatifan	• Data from one or more of the early-line cohorts of ARC-20 and go / no go decision on the Phase 3 portion of eVOLVE-RCC02 • Target initiation of first phase 3 study for cas in an early-line setting of ccRCC
2026 (event-driven)	STAR-221	Domvanalimab	• Phase 3 data for dom + zim + chemo vs. nivo + chemo in 1L gastric cancer

1L: first-line; 2L: second-line; chemo: chemotherapy; dom: domvanalimab; ESMO: European Society for Medical Oncology; mono: monotherapy; nivo: nivolumab; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; QD: once daily; zim: zimberelimab

Our Partnerships Enable Cost-Efficiency and Greatly Expand Our Opportunities

	GILEAD	TAIHO PHARMA	AstraZeneca
R&D COST-SHARING	STAR-121 STAR-221 EDGE-Gastric EDGE-Lung VELOCITY-Lung	STAR-121 STAR-221 PRISM-1 PEAK-1	PACIFIC-8 eVOLVE RCC02
RIGHTS / ECONOMICS	• Arcus retains co-promotion rights and profit share in the U.S. • High-teens to low-20's royalties on ex-U.S. sales • Opt-in rights to programs (except casdatifan)	• Taiho has development / commercial rights in Japan and rest of Asia (ex-China) • Up to $275mm in milestones per program • High single-digit to mid-teens royalties	• Both parties retain economics on their respective molecules

cas: casdatifan; mm: million; R&D: research & development

ARCUS BIOSCIENCES

Casdatifan (HIF-2α) in ccRCC

Casdatifan is Poised to Become the HIF-2α Treatment of Choice

A BEST-IN-CLASS CLINICAL PROFILE

- Based on data from 121 patients, **cas has shown higher ORR, ~50% lower rate of primary progressive disease, and >2x longer median PFS** relative to published studies for belzutifan**
- Cas + cabo has shown a 46% ORR vs 31% for belzutifan + cabo**
- Similar rates of anemia and hypoxia compared to marketed dose of belzutifan**

BROAD AND DIFFERENTIATED DEVELOPMENT PLAN

- Global Phase 3 PEAK-1 study currently enrolling and evaluating cas + cabo in IO-experienced ccRCC represents a **"fast-to-market" opportunity**
- **Evaluating multiple early-line strategies** based on eVOLVE and encouraging, emerging data from "early-line" cohorts of ARC-20 (cas + anti-PD-1 in 1L ccRCC, cas mono in IO-experienced ccRCC, cas mono in 1L favorable risk ccRCC)

STRATEGIC OPTIONALITY AND EXTERNAL VALIDATION

- **Casdatifan rights are wholly-owned by Arcus in the major markets (ex-Japan*),** enabling significant strategic optionality
- Taiho's recent opt-in further validates casdatifan's best-in-class profile and market potential

*and certain other Asian territories, excluding China

** Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

cas: casdatifan; ccRCC: clear cell renal cell carcinoma; cabo: cabozantinib; h: hours; IO: immuno-onncology ORR: overall response rate

ARCUS BIOSCIENCES

With a Differentiated Efficacy Profile and Development Plan, Cas is Well Positioned in a Two-Horse Race

EFFICACY & SAFETY DATA BASED ON ARC-20 (CAS) AND LITESPARK-005 (BELZ), MONOTHERAPY DATA IS FOR PATIENTS THAT HAVE RECEIVED BOTH PRIOR ANTI-PD-1 AND TKI

	casdatifan 100mg QD	belzutifan[1]
		
Primary PD rate for monotherapy	**16%**	34%
cORR for monotherapy	**35% (42% uORR*)**	22%
mPFS for monotherapy	**12+ months**	5.6 months
cORR in combination with cabo ("IO-experienced")	**46%**	31%
TKI partner in post-IO setting	**+ cabo**	+ lenva
1L / "Early-line" Strategy	**+ volru and / or other cas-regimen**	+ pembro/lenva
Pill burden	**1 (+1 for cabo)**	3 (+2 for lenva)

*Includes two unconfirmed responses, both pending confirmation, in the 100mg cohort. One was recorded prior to the DCO, and one was recorded after the DCO. If both confirm, the cORR for the 100mg cohort would increase from 35% to 42% and the cORR for the pooled analysis would increase from 31% to 33%. DCO for casdatifan data: August 15, 2025

1. Clinical data from LITESPARK-005. Sources: Albiges L. et al. Abstract LBA88, ESMO 2023; Choueiri et al. 2024.

Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

1L: first-line; belz: belzutifan; cabo: cabozantinib; cas: casdatifan; ccRCC: clear-cell renal cell carcinoma; cORR: confirmed overall response rate; DCO: data cutoff; IO: immunotherapy; lenva: lenvatinib; mPFS: median progression free survival; m: months; pembro: pembrolizumab; QD: once daily; TKI: tyrosine kinase inhibitor; uORR: unconfirmed overall response rate; volru: volrustomig

Strategy to Advance Casdatifan into 1L ccRCC

eVOLVE-RCC02 Ph 1b/3 Study

- Evaluating casdatifan + volrustomig, AstraZeneca's anti-PD-1/CTLA-4 bi-specific, in 1L ccRCC; sponsored and operationalized by AstraZeneca
- Following rapid recruitment into the study, new enrollment was paused following observations of potentially immune-mediated AEs
  - The AEs were Grade 3 or lower and no Grade 4 or 5 AEs have been observed to date
- Patients already enrolled will continue to be treated; longer-term follow-up data, along with any discussions with health authorities, will inform next steps for the study

1L Strategies for Casdatifan

- eVOLVE-RCC-002 and encouraging data from the new cohorts added to ARC-20 will inform future front-line development strategies for cas
- Data from these cohorts will inform other cas-containing regimens, including in combination with SOC, that could be advanced into Phase 3
- Data from at least one of these cohorts will be presented in 2H:26

Goal is to start one Phase 3 trial in an early-line ccRCC setting in 2H 2026

1L: first-line; AE: adverse event; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; PD-1: programmed cell death protein 1; SOC: standard of care

Our Initial Focus Is on the IO-naive and Post-IO Settings, Both Multi-Billion Dollar Market Opportunities

	CURRENT SOC	POTENTIAL FUTURE TREATMENT	MARKET SIZE (MAJOR MARKETS[1,2])
1L metastatic	PD-1 + CTLA4	eVOLVE RCC02 cas + volru Other cas-containing regimens	21k patients ~$3B OPPORTUNITY
Post-IO metastatic	TKI mono	PEAK-1 cas + cabo	19k patients ~$2B OPPORTUNITY
Post-IO & Post-TKI	mTOR, TKI, HIF-2α		12k patients

3 cohorts in ARC-20 to inform future studies in early line settings:

- 1L (cas + zim)
- 1L favorable risk (cas mono)
- 1L/2L Post-IO / TKI-naive (cas mono)

1. Drug Treatable Addressable Populations (Major Markets, 2024); Decision Resources Group, Arcus analysis
2. Major Markets (US, EU5, JP) - total projected 2034

1L: first-line; 2L: second-line; B: billion; cabo: cabozantinib; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; IO: immunotherapy; mono: monotherapy; mTOR: mammalian target of rapamycin inhibitor; SOC: standard of care; TKI: tyrosine kinase inhibitor; volru: volrustomig; zim: zimberelimab

Casdatifan (HIF-2α) in Late-Line ccRCC

Casdatifan Monotherapy Data Presented at October 6, 2025 Investor Event

Data Presented at October 2025 Investor Event Support Cas's Best-in-Class Profile

- For the first time, we presented data from all four late-line monotherapy cohorts from ARC-20, including PFS – a 121-patient dataset

- Across this dataset (n=121), we have observed*:
  - ✓ **Substantially higher ORR vs. that of belzutifan**
  - ✓ **~50% lower rate of primary progressive disease**
  - ✓ **~2x longer median PFS**
  - ✓ **Faster time to response**

- Responses observed have been highly durable with the vast majority of patients still on treatment

- We believe these data substantially de-risk PEAK-1 and demonstrate the potential for casdatifan to displace TKIs in earlier line settings

*Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

Cas: casdatifan; ORR: overall response rate; PFS: progression-free survival; TKI: tyrosine kinase inhibitor

ARCUS BIOSCIENCES

Patients in ARC-20 Had Greater Number of Prior Therapies Relative to the Patients in LITESPARK-005

	Dose Expansion: 2L+ ccRCC					Belzutifan[3]
Safety-Evaluable Population[1]	50mg BID (n = 33)	50mg QD (n = 31)	100mg QD (n = 32)	150mg QD (n = 31)	Pooled (n = 127)	120mg QD (n = 374)
Age, years, median (range)	62 (41–79)	65 (43–82)	60 (45–77)	65 (53–78)	62 (41–82)	66 (49–78)
Sex, Female/Male, n (%)	8 (24) / 25 (76)	10 (32) / 21 (68)	5 (16) / 27 (84)	8 (26) / 23 (74)	31 (24) / 96 (76)	77 (21) / 297 (79)
ECOG PS 0/1, n (%)	16 (48) / 17 (52)	18 (58) / 13 (42)	15 (47) / 17 (53)	13 (42) / 18 (58)	62 (49) / 65 (51)	NA
IMDC Risk Score, n (%)[2]						
Favorable	10 (30)	8 (26)	7 (22)	9 (29)	34 (27)	79 (21)
Intermediate	21 (64)	17 (55)	20 (63)	19 (61)	77 (61)	249 (67)
Poor	2 (6)	5 (16)	3 (9)	3 (10)	13 (10)	46 (12)
Prior lines of therapy, n (%)						
1	**2 (6)**	**5 (16)**	**5 (17)**	**7 (23)**	**21 (17)**	**46 (12)**
2	**14 (42)**	**9 (29)**	**7 (24)**	**6 (19)**	**39 (30)**	**157 (42)**
3	**8 (24)**	**8 (26)**	**10 (34)**	**7 (23)**	**33 (26)**	**171 (46)**
4 or more	**9 (27)**	**9 (29)**	**7(24)**	**11 (36)**	**35 (28)**	**0 (0)**

DCO date: August 15, 2025
1. The safety-evaluable population included all dose expansion enrolled patients who received any amount of study treatment.
2. One patient in the 50mg QD group had an unknown IMDC risk score and one patient in the 100mg QD group had a missing IMDC risk score.
3. IA1 for LITESPARK-005. Source: Albiges L. et al. Abstract LBA88, ESMO 2023; *2 or 3 prior VEGF-R TKI regimens; DCO date: August 30, 2024.; Baseline was defined as the last non-missing assessment prior to the first dosing of treatment.
Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.
2L: second-line; BID: twice daily; ccRCC: clear cell renal cell carcinoma; DCO: data cutoff; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; QD: once daily; VEGFR-TKI: vascular endothelial growth factor receptor tyrosine kinase inhibitor

Confirmed ORR for the "Pooled" Cohort (n=121) is >30%

Efficacy-Evaluable Population[1]	Dose Expansion: 2L+ ccRCC					Belzutifan[2]
	50mg BID (n = 31)	50mg QD (n = 28)	100mg QD (n=31)	150mg QD (n = 31)	All Pooled (n = 121)	120mg QD (n = 374)
Median Follow-Up, mos (range)	22.8 (14.4, 26.0)	19.7 (15.9, 21.3)	12.4 (6.3, 13.5)	14.4 (12.5, 15.5)	15.2 (6.3, 26.0)	18.4 (9.4–31.7)
Median Time to Response, mos	**2.7**	**4.1**	**2.6**	**2.7**	**2.8**	**3.8**
Confirmed ORR (95% CI)	**26% (12, 45)**	**36% (19, 56)**	**35% (19, 55)**	**29% (14, 48)**	**31% (23, 40)**	**22% (18, 27)**
Complete Response, % (n)	0% (0)	4% (1)	0% (0)	0% (0)	1% (1)	3% (10)
Partial Response, % (n)	26% (8)	32% (9)	35% (11)	29% (9)	31% (37)	19% (72)
Stable Disease, % (n)	55% (17)	50% (14)	48% (15)	45% (14)	50% (60)	39% (147)
Progressive Disease, % (n)	19% (6)	14% (4)	16% (5)[3]	26% (8)	19% (23)[3]	34% (126)
ORR, including responses pending confirmation (95% CI)*	26% (12, 45)	36% (19, 56)	42% (25, 61)	29% (14, 48)	33% (25, 42)	NA

*Includes two unconfirmed responses, both pending confirmation, in the 100mg cohort. One was recorded prior to the DCO, and one was recorded after the DCO. If both confirm, the cORR for the 100mg cohort would increase from 35% to 42% and the cORR for the pooled analysis would increase from 31% to 33%.

DCO date: August 15, 2025
1. Efficacy-evaluable population for this expansion cohort is defined as all eligible participants who received any study treatment and have at least one post-baseline efficacy assessment, or who discontinued study treatment due to progressive disease or death, regardless of whether they had a scan.
2. IA1 for LITESPARK-005. Source: Albiges L. et al. Abstract LBA88, ESMO 2023; *2 or 3 prior VEGF-R TKI regimens; DCO date: August 30, 2024; Baseline was defined as the last non-missing assessment prior to the first dosing of treatment.
3. Includes three patients with radiological progressive disease and two patients who had clinical progression before the first scan, which have been included by do not meet criteria for progressive disease per RECIST.
Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.
2L: second-line; BID: twice daily; ccRCC: clear cell renal cell carcinoma; CI: confidence interval; cORR: confirmed overall response rate; DCO: data cutoff; NA: not applicable; ORR: overall response rate; QD: once daily; RECIST: Response Evaluation Criteria in Solid Tumors; VEGFR-TKI: vascular endothelial growth factor receptor tyrosine kinase inhibitor

Median PFS for the 100mg QD Cohort Has Still Not Been Reached with >12 Months Follow-Up

Median PFS, months (95% CI)	Median follow-up (range)
Not reached (5.7, NE)	**12.4** (6.3, 13.5)



PFS Landmarks	% (95% CI)
6 Months	67% (48, 81)
12 Months	**60%** (40, 75)

Number at Risk

31	25	20	17	8	0

60% Landmark 12-Month PFS compares very favorably to the 34% for belzutifan in LITESPARK-005*

DCO date: August 15, 2025

*Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

CI: confidence interval; DCO: data cutoff; NE: not estimable; PFS: progression-free survival; QD: once daily

Median PFS for the Four Monotherapy Cohorts Pooled (n=121) is 2x+ the mPFS for Belz Monotherapy in LS-005



Median PFS, months (95% CI)	Median follow-up (range)
12.2 (9.4, 20.6)	**15.2** (6.3, 26.0)

PFS Landmarks	% (95% CI)
12 Months	50% (41, 59)
18 Months	**43%** (33, 53)

Number at Risk

0	3	6	9	12	15	18	21	24
121	88	72	66	48	22	20	6	0

12.2 months mPFS compares to 5.6 mos PFS for belzutifan in LITESPARK-005*

DCO date: August 15, 2025

*Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

Belz: belzutifan; CI: confidence interval; DCO: data cutoff; mPFS: median progression-free survival; PFS: progression-free survival

With a 12+ Month PFS, Casdatifan Exceeds All PFS Benchmarks for Monotherapy

Earlier-line patient populations

TRIAL	TRIAL RECRUITMENT COMPLETION YEAR	PATIENT POPULATION	TRIAL DESIGN	cORR	mPFS
ARC-20 (Phase 1b/2)	**2025**	**PDx/TKI Experienced ccRCC (mostly 3L+)**	**Cas (Pooled)** **Cas (100mg QD)**	**31%** **35%**	**12.2m** **Not reached**
TIVO-3 (Phase 3)[1]	2017	3L-4L TKI Experienced ccRCC	Tivozanib vs. sorafenib	**18%** vs. 8%	**5.6m** vs. 3.9m
LITESPARK-005 (Phase 3)[2]	2022	PDx/TKI Experienced ccRCC (mostly 3L-4L)	Belz vs. everolimus	**22%** vs. 4%	**5.6m** vs 5.6m
RECORD-1 (Phase 3)[3]	2007	ccRCC with prior sunitinib and/or sorafenib (mostly 3L+)	Everolimus + BSC vs placebo + BSC	**2%** vs. 0%	**4.9m** vs. 1.9m
METEOR (Phase 3)[4]	2014	2L+ TKI Experienced ccRCC (mostly 2L)	Cabo vs everolimus	**17%** vs. 3%	**7.4m** vs. 3.9m
Lenva + ev (Phase 2)[5]	2013	2L TKI Experienced ccRCC	Lenva + everolimus vs. Lenva vs. everolimus	43% vs. **27%** vs 6%	14.6m vs. **7.4m** vs. 5.5m
AXIS (Phase 3)[6]	2010	2L ccRCC	Axitinib vs sorafenib	**19%** vs. 9.9%	**6.7m** vs. 4.7m
CONTACT-03 (Phase 3)[7]	2021	PDx Experienced ccRCC (did not require prior TKI)	Atezo + cabo vs. cabo	41% vs. **41%**	10.6m vs. **10.8m**
CANTATA[8]	2019	PDx Experienced ccRCC (did not require prior TKI)	Tela + cabo vs. cabo	31% vs **28%**	9.2m vs. **9.3m**

DCO date for casdatifan: August 15, 2025

1. Rini et al 2020 (TIVO-3); 2. Choueiri et al 2024 (LS-005); 3. Motzer et al 2010 (RECORD-1); 4. Choueiri et al 2016 (METEOR); 5. Motzer et al 2015 (lenva +everolimus); 6. Rini et al 2011 (AXIS); 7. Pal et al 2023 (CONTACT-03); 8. Tannir et al 2022 (CANTATA)

Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

2L: second-line; 3L: third-line; 4L: fourth-line; atezo: atezolizumab; belz: belzutifan; BSC: Biopharmaceutics Classification System; cabo: cabozantinib; cas: casdatifan; cORR: confirmed overall response rate; ccRCC: clear cell renal cell carcinoma; DCO: data cutoff; lenva: lenvatinib; m: months; mPFS: median progression-free survival; PFS: progression-free survival; tela: teleglenastat; TKI: tyrosine kinase inhibitor

Casdatifan Was Well Tolerated in All Cohorts, With a Comparable Safety Profile to That of Belzutifan

Safety-Evaluable Population[1]	50mg BID (n=33)	50mg QD (n=31)	100mg QD (n=32)	150mg QD (n=31)	Pooled (n=127)	Belzutifan (LITESPARK-005)[1]
Anemia, n (%)						**Anemia:**
All grades	29 (88)	29 (94)	29 (91)	30 (97)	117 (92)	All grade: 83%
Grade ≥3 related to casdatifan	16 (49)	12 (39)	8 (25)	16 (52)	52 (41)	Grade 3+: 33%
Related to casdatifan leading to interruptions	11 (33)	10 (32)	9 (28)	15 (48)	45 (35)	
Leading to dose reductions	4 (12)	5 (16)	3 (9)	6 (19)	18 (14)	
Leading to discontin.	**0**	**0**	**0**	**0**	**0**	
Hypoxia, n (%)						**Hypoxia:**
All grades	6 (18)	5 (16)	5 (16)	7 (23)	23 (18)	All Grade: 15%
Grade ≥3 related to casdatifan	3 (9)	3 (10)	3 (9)	5 (16)	14 (11)	Grade 3+: 11%
Related to casdatifan leading to interruptions	5 (15)	4 (13)	3 (9)	6 (19)	18 (14)	
Leading to dose reductions	3 (9)	2 (6)	1 (3)	3 (10)	9 (7)	
Leading to discontin.	**0**	**1 (3)**	**1 (3)**	**1 (3)**	**3 (2)**	

DCO date: August 15, 2025

1. Source: Albiges L. et al. Abstract LBA88, ESMO 2023

Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors.

BID: twice daily; DCO: data cutoff; QD: once daily

ARCUS BIOSCIENCES

Development Strategy for Casdatifan in IO-Experienced and 1L ccRCC

First Phase 3 Study for Cas Has a Simple Design that Utilizes the Preferred SOC in Post-IO ccRCC



✓ **PEAK-1 Initiated**

1L: first-line; cabo: cabozantinib: cas: casdatifan; ccRCC: clear cell renal cell carcinoma; DCR: disease control rate; DOR: duration of response; HIF: hypoxia-induced factor; IO: immuno-oncology; mg: milligram; ORR: objective response rate; OS: overall survival; PD-1/PD-L1: programmed death protein 1/programmed death ligand 1; PFS: progression free survival; RCC: renal cell carcinoma; RECIST: Response Evaluation Criteria in Solid Tumors

Cas + Cabo Data Presented at ASCO Substantially De-Risk PEAK-1

ROBUST EFFICACY	• The 46% cORR for cas + cabo **exceeds benchmarks for either agent alone[1] and the Phase 2 LITESPARK-003 benchmark for belz + cabo[2]**
RESPONSES ALREADY APPEAR DURABLE	• **All responses to date have confirmed** and all 11 responders remain on treatment as of July 28, 2025 • Majority of patients with best response of SD also remain on treatment, indicating that even SD patients are experiencing meaningful benefit
NO SIGNS OF OVERLAPPING TOXICITY	• **AE profile for cas + cabo is consistent with that expected for either agent alone** • No cas-related TEAEs > grade 3
HIGH DOSE INTENSITY OF BOTH DRUGS	• **88-95% dose intensity achieved for both cas and cabo** enabling optimization of efficacy for the combination • As of the DCO, only 5% of safety evaluable patients discontinued a drug due to an AE and no patients have discontinued both drugs

DCO date: March 14, 2025.

1. For cabo monotherapy - Phase 3, CONTACT-03 , Pal et al 2023; Phase 3 METEOR, Choueiri et al 2015; cas monotherapy: Arcus ENA 2024 presentation
2. Choueiri et al. 2023, Lancet Oncology

AE: adverse event; belz: belzutifan; cabo: cabozantinib; cas: casdatifan; cORR: confirmed overall response rate; DCO: data cutoff; IO: immunotherapy; SD: stable disease; TEAE: treatment-emergent adverse event

2025 ASCO ANNUAL MEETING #ASCO25
May 30 – June 3, 2025
McCormick Place | Chicago, IL & Online
am.asco.org

Almost All Patients in Cas + Cabo Cohort Achieved Tumor Reduction[a,b]



Presented at ASCO 2025 by Toni K Choueiri, MD, FASCO. DCO date: March 14, 2025.
[a]All eligible patients who received any study treatment and achieved a minimum of 12 weeks follow-up or discontinued due to progression or death.
[b]Inclusive of one patient who had confirmed PR after March 14, 2025.
Cabo: cabozantinib; cas: casdatifan; DCO: data cutoff; SLD: sum of lesion diameter

ARCUS BIOSCIENCES

2025 ASCO ANNUAL MEETING #ASCO25
May 30 – June 3, 2025
McCormick Place | Chicago, IL & Online
am.asco.org

Tumor Reduction Has Deepened Over Time and Responses Already Appear Very Durable for Cas + Cabo



DCO date: March 14, 2025.
All eligible patients who received any study treatment and achieved a minimum of 12 weeks follow-up or discontinued due to progression or death.
Cabo: cabozantinib; cas: casdatifan; DCO: data cutoff; SLD: sum of lesion diameter

ARCUS BIOSCIENCES

Casdatifan Dose Intensity was Consistently 95%+, Driving Efficacy and Durability

	CAS 100MG QD + CABO 60MG QD* N=27	CAS 100MG QD* N=29	CAS 50MG QD* N=31	CAS 50MG BID* N=33
Median duration of follow-up, months	3.7	5.1	12.3	15.5
Median Tx duration, months	3.0	4.1	10.6	7.1
Cas relative dose intensity, median	**94.9%**	**98.6%**	**100.0%**	**98.6%**
Cabo relative dose intensity, median	**88.0%**	NA	NA	NA

*DCO date: January 3, 2025
BID: twice daily; cabo: cabozantinib; cas: casdatifan; DCO: data cutoff; NA: not applicable; QD: once daily; tx: therapy

Very Few Grade 3 or Higher Treatment Related AEs in Cas + Cabo Cohort

- No casdatifan-related grade 4 or 5 AEs were observed

	SAFETY POPULATION,[a] n (%) (N = 42)		
	GRADE 3 OR HIGHER AE RELATED TO:		
	casdatifan	cabozantinib	any study drug
Patients with any treatment-related ≥ grade 3 AE[b]	13 (31%)	16 (38%)	20 (48%)
Anemia	10 (24%)	6 (14%)	10 (24%)
Hyponatremia	0	3 (7%)	3 (7%)
Hypoxia	3 (7%)	0	3 (7%)
Hypertension	0	2 (5%)	2 (5%)
Neutrophil count decreased	1 (2%)	2 (5%)	2 (5%)

Presented at ASCO 2025 by Toni K Choueiri, MD, FASCO. DCO date: March 14, 2025.

[a]Safety population included patients who received any amount of study drug and had at least 1 month of safety follow-up at the data cutoff date.
[b]Treatment-emergent adverse events (grade 3 or higher) related to casdatifan, cabozantinib, or any study drug reported in ≥ 3% of patients in any treatment arm.
AE: adverse event; cabo: cabozantinib; cas: casdatifan; DCO: data cutoff

ARCUS BIOSCIENCES

Emerging Data Will Support Casdatifan's Early-Line Registrational Strategy

eVOLVE RCC02

1L ccRCC
casdatifan + volrustomig (anti-PD-1/CTLA-4 bispecific)

Potential anti-PD-1 / CTLA-4 + HIF-2α combination

Initial Data and Go / No Go Decision on Phase 3 Expected in 2H:26

ARC-20

Favorable-risk 1L ccRCC
casdatifan mono

Potential for cas mono in favorable risk patients where no SOC exists

1L ccRCC
casdatifan + zimberelimab (anti-PD-1)

Potential for cas + anti-PD-1 combinations in 1L ccRCC

Initial Data Expected to be Presented in 2H:26

Post-IO ccRCC
casdatifan mono

Potential for cas mono to displace TKI mono in IO-experienced patients

Goal is to start one Phase 3 trial in an early-line ccRCC setting in 2H 2026

1L: first-line; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; IO: immunotherapy; mono: monotherapy; PD-1: programmed cell death protein 1; SOC: standard of care; TKI: tyrosine kinase inhibitor

ARCUS BIOSCIENCES

eVOLVE-RCC02: Seamless Phase 1b/3 Design to Evaluate Cas + Volru in 1L Advanced ccRCC

PATIENT POPULATION:
- Advanced ccRCC
- **No prior systemic therapy for a/m RCC**

PHASE 1B

R 1:1

ARM 1A
volrustomig + casdatifan

ARM 1B
volrustomig + casdatifan

PRIMARY ENDPOINT:
- Safety

SECONDARY ENDPOINTS:
- ORR, DOR, PFS, DCR

PHASE 3

R 1:1:1

ARM 3A
volrustomig + casdatifan

ARM 3B
volrustomig monotherapy

ARM 3C (SOC)
nivolumab + ipilimumab

PRIMARY ENDPOINTS:
- PFS
- OS

KEY SECONDARY ENDPOINTS:
- ORR, DOR

Sponsored by AstraZeneca

- Phase 1b enrollment paused; patients already enrolled will continue to be treated
- Longer-term follow-up data, along with any discussions with health authorities, will inform next steps

1L: first-line; a/m: advanced or metastatic; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; DCR: disease control rate; DOR: duration of response; ORR: objective response rate; OS: overall survival; P: poor risk; PFS: progression free survival; RCC: renal cell carcinoma; SOC: standard of care; volru: volrustomig

Domvanalimab in Upper GI Cancers and Non-Small Cell Lung Cancer

Dom is the Most Clinically Advanced Fc-Silent Anti-TIGIT Antibody in Development

TIGIT inhibition turns an immuno-suppressive "brake" into an accelerator of adaptive immunity

1 **Dom blocks TIGIT, an inhibitory "brake" on immune cells,** from binding to CD155 (PVR) on tumor cells

2 TIGIT blockade **enables PVR to bind CD226 (DNAM-1), an "accelerator" on immune cells,** driving tumor cell kill



First-to-Market potential in Upper GI & the only Fc-silent anti-TIGIT in Ph3 NSCLC

Fc-silent

Avoids depletion of TIGIT-bearing cells:

- Minimizes treatment interruptions by avoiding Treg depletion-related immune AEs
- Maximizes efficacy by avoiding potential depletion of cancer-fighting Teff cells

Individual Agents

Administered as individual agents (vs. co-formulation)

- Pursuing 30-minute co-administration infusion time for dom and zim

Optimized Development Strategy

Positioned to be first to market in 1L gastric, 1L NSCLC (all-comers) and Stage 3 NSCLC

Note: co-administration of dom + zim was not part of STAR-121 Phase 3 study in 1L NSCLC
1L: first-line; AE: adverse event; DNAM-1: DNAX accessory molecule; dom: domvanalimab; GI: gastrointestinal; NSCLC: non-small cell lung cancer; Ph: phase; Teff: effector T-cells; Treg: regulatory T-cells; zim: zimberelimab

Readouts for Phase 2 Studies for Dom/Zim De-Risk Phase 3 Studies

Phase 2 Study		Phase 3 Study
EDGE-Gastric: Dom + Zim + Chemo in 1L Upper GI Adenocarcinomas	Same regimen and patient population	STAR-221: Dom + Zim + Chemo vs. Nivo + Chemo in 1L Upper GI Adenocarcinomas
ARC-7: Dom + Zim in 1L PD-L1 High NSCLC ARC-10: Dom + Zim vs. Chemo in 1L PD-L1 High NSCLC	Demonstrated activity for dom/zim in NSCLC	STAR-121: Dom + Zim + Chemo vs. Pembro + Chemo in 1L PD-L1>1% NSCLC

1L: first-line; chemo: chemotherapy; dom: domvanalimab; GI: gastrointestinal; NSCLC: non-small cell lung cancer; nivo: nivolumab; PD-L1: programmed cell death ligand 1; pembro: pembrolizumab; zim: zimberelimab

Unprecedented mOS Data from EDGE-Gastric Were Presented at ESMO 2025

Phase 2 EDGE-Gastric OS Results (n=41)

Janjigian et al. ESMO, Oct. 18, 2025; DCO date of March 3, 2025

	Median OS, mo (90% CI)	24-mo OS rate, % (90% CI)
Overall	26.7 (18.4, NE)	50% (36, 63)



Phase 2 EDGE-Gastric Data Exceeded Phase 3 Benchmark Data

		EDGE-GASTRIC	CHECKMATE-649[1]	KEYNOTE-859[2]	RATIONALE-305[3]
mOS	ITT	**26.7m**	13.7m	12.9m	15.0m
	PD-L1 High	**NR**	14.4m	13.0m	17.2m
mPFS	ITT	**12.9m**	7.7m	6.9m	6.9m
	PD-L1 High	**14.5m**	8.3m	8.1m	7.2m
ORR	ITT	**59%**	58%[4]	51%	47%
	PD-L1 High	**69%**	60%	61%	50%

Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors

1. Phase 3: Janjigian et al, 2024. (36.2m minimum follow up) 2. Phase 3: Rha, ESMO Virtual Plenary Feb 2023 and ASCO 2023 #4014 (31.0m median follow up) 3. Phase 3: Moehler, ASCO GI 2023 #286 (15.9m median follow up), and Xu, ESMO 2023 LBA80 (24.6m minimum follow up) 4. ITT population for Checkmate-649 included ~60% patients with PD-L1 high status at baseline. Note that EDGE-Gastric overall population included only 39% PD-L1 high at baseline.
CI: confidence interval; DCO: data cutoff; dom: domvanalimab; ITT: intent-to-treat; KM: Kaplan Meyer; mOS: median overall survival; mPFS: median progression-free survival; NE: not estimable; NR: not reached; ORR: overall response rate; PD-L1: programmed cell death ligand 1

Phase 3 Study was Fully Enrolled in June 2024

Dom + zim is positioned to be the first anti-TIGIT combination approved

STAR-221 is evaluating the same regimen in the same setting as EDGE-Gastric



Stratification Factors:

- PD-L1 expression (TAP ≥5% or TAP <5%)
- ECOG PS (0 or 1)
- Region (US/Canada/EU5 vs. Asia vs. rest of world)

*PI choice of chemo: FOLFOX or CAPOX.
NCT #: NCT05568095
1L: first-line; chemo: chemotherapy; dom: domvanalimab; EAC: esophageal adenocarcinoma; ECOG PS: Eastern Cooperative Oncology Group performance status; GEJ: gastroesophageal junction; nivo: nivolumab; ITT: intent-to-treat; OS: overall survival; PFS: progression-free survival; PI: principal investigator; TAP: tumor area positivity; R: randomized; w/o: without; zim: zimberelimab

ARC-7 and ARC-10 Demonstrated Consistent Improvement for Dom + Zim in 1L PD-L1 High NSCLC

ARC-7 1L PD-L1 High NSCLC

dom + zim *vs.* zim *vs.* etruma + dom + zim (n=150)

Johnson, et al. ASCO, Jun. 2, 2023; DCO date of Feb. 7, 2023

2023 ASCO ANNUAL MEETING

	Dom + Zim	Zim
Median PFS [95% CI]	9.3 months [4.1,NE]	5.4 months [2.7,9.7]
Events (%)	27 (54%)	32 (64%)
HR [95% CI]	**0.67 [0.4,1.13]**	



Dom + Zim vs. Zim PFS HR = 0.67

ARC-10 1L PD-L1 High NSCLC

dom + zim *vs.* zim *or* chemo (n=95)

Johnson, et al. SITC 2024; DCO date of May 17, 2024

Society for Immunotherapy of Cancer sitc2024 NOV. 6-10 | HOUSTON

	Dom + Zim	Zim
Median OS [95% CI]	NR [13.7,NE]	24.4 months [7.8, NE]
HR [95% CI]	**0.64 [0.32,1.25]**	



Dom + Zim vs. Zim OS HR = 0.64

1L: first-line; chemo: chemotherapy; CI: confidence interval; DCO: data cutoff; dom: domvanalimab; etruma: etrumadenant; HR: hazard ratio; NE: not estimable; NR: not reached; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; SITC: Society for Immunotherapy of Cancer; zim: zimberelimab

ARCUS BIOSCIENCES

Phase 3 Study Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC (All PD-L1 Subgroups)

Uses standard of care, pembrolizumab, in the comparator arm



Strat Factors:
- Baseline PDL1 PD-L1 status (<50% vs ≥50%)
- Geography (east Asia vs non-east Asia)
- Histology (Sq vs Non-sq)

★ ONGOING

Gilead Sciences is operationalizing STAR-121.
NCT #: NCT05502237
1L: first-line; BICR: blinded independent central review; chemo: chemotherapy; dom: domvanalimab; DOR: duration of response; ECOG: Eastern Clinical Oncology Group; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; pembro: pembrolizumab; PD-L1: programmed cell death ligand 1; PFS: progression-free survival; QoL: quality of life; R: randomized; sq: squamous; zim: zimberelimab

Phase 3 Study Evaluating Dom + Durva vs Placebo + Durva in Unresectable, Stage III NSCLC

Uses durvalumab, the standard-of-care in Stage III NSCLC, in both arms



Strat Factors:
- Disease stage prior to cCRT (IIIA vs. IIIB/IIIC)
- PD-L1 status (TC ≥ 50% vs. TC 1-49%), as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay
- Histology (Sq vs Non-sq)

★ ONGOING

NCT #: NCT05211895

cCRT: concurrent chemoradiotherapy; dom: domvanalimab; durva: durvalumab; IHC: immunohistochemistry; ITT: intent to treat; m: months; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; Q4W: every 4 weeks; R: randomized; sq: squamous; TC: tumor count; wt: wild type

Quemliclustat in Pancreatic Cancer

Quemliclustat: A Small Molecule CD73 Inhibitor with Several Key Attributes

QUEMLICLUSTAT

- Highly potent small molecule
- Target coverage achieved at doses as low as 25mg Q2W
- Extremely long (4+ days) half-life, enabling Q2W dosing by IV infusion

Biological rationale for CD73 inhibition in pancreatic cancer

- Pancreatic cancer exhibits very high expression of CD73, the main source of intra-tumor adenosine
- Immunogenic chemotherapy (e.g., gemcitabine/nab-paclitaxel) releases ATP and contributes to adenosine production
- Tumors such as pancreatic cancer become sensitive to immune attack if adenosine production (i.e., CD73 activity) is blocked by quemli while administering SOC chemotherapy

Potential advantages over CD73 antibodies[1]

- ✓ Highly potent and selective inhibition of both tumor cell-bound and soluble CD73
- ✓ Greater inhibition of enzymatic production of adenosine
- ✓ Orders of magnitude more potent
- ✓ Greater permeability of tumor tissue

Quemliclustat is an investigational molecule and its safety and efficacy have not been established.
1. Arcus Biosciences data on file; based on preclinical studies
ATP: adenosine triphosphate; IV: intravenous; quemli: quemliclustat; Q2W: every 2 weeks

Highlights from the Randomized Phase 1 Study in 1L PDAC

Wainberg ZA, et al. ASCO GI Jan. 19, 2024, DCO date of June 19, 2023

- **Median overall survival (mOS) was 15.7 months** (n=122) for patients treated with a quemliclustat-based regimen, which exceeds the historical benchmark data for chemotherapy alone (8.5 – 11.7 months)[1,2]
- **A 37% reduction in risk of death and a 5.9-month improvement in mOS was observed** for patients treated with the quemli-based regimen when compared to a synthetic control arm of patients treated with G/nP alone[1]
- **The quemli-based regimen was well-tolerated**, with no new safety signals or significant added toxicity compared to chemotherapy alone[1]

- **Enrollment completed for Phase 3 PRISM-1 study**

1. Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, DCO date of June 19, 2023
2. Abraxane USPI, 2020 and Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. doi:10.1016/S0140-6736(23)01366-1

1L first-line; DCO: data cutoff; G/nP: gemcitabine/nab-paclitaxel; mOS: median overall survival; PDAC: pancreatic ductal adenocarcinoma; quemli: quemliclustat

PRISM-1

Phase 3 Study of Quemli + Chemo in 1L Metastatic PDAC

1L: first-line; ECOG PS: Eastern Cooperative Oncology Group performance status; GnP: gemcitabine/nab-paclitaxel; PDAC: pancreatic ductal adenocarcinoma; OS: overall survival; PFS: progression-free survival; N: number; Q2W: every two weeks; quemli: quemliclustat; YE: year end

ARCUS BIOSCIENCES

Our Emerging I&I Portfolio

Our I&I Drug Discovery Strategy

IN-HOUSE EXPERTISE IN IMMUNOLOGY has been a core aspect of our discovery group since Arcus founding

MINIMIZE BIOLOGICAL RISK by leveraging validated mechanisms with applications to common diseases with large addressable populations

2-PRONG I&I STRATEGY:

- Small-molecule improvements of cytokine-targeted therapeutics with validated clinical benefit
- Target immune cell types that play key roles in human disease and have been historically “under-studied”
  - Multi-year interest in mast cell biology (e.g., KIT, MRGPRX2), neutrophil biology

I&I: immunology and inflammation; KIT: tyrosine kinase receptor for stem cell factor SCF; MRGPRX2: mas-related G protein-coupled receptor member X2

Our I&I Drug Discovery Portfolio

TARGET	MODALITY	DISEASE AREA	STATUS
MRGPRX2	SM	CSU, AD	Preclinical
TNF-α (TNFR1)	SM	RA, Psoriasis, IBD	Advanced Discovery
CCR6	SM	Psoriasis	Advanced Discovery
CD89	mAb	RA	Advanced Discovery
CD40L	SM	SLE; MS	Discovery

We expect to select development candidates for at least 3 of these programs within the next 12 months

AD: atopic dermatitis; CSU: chronic spontaneous urticaria; IBD: inflammatory bowel disease; I&I: immunology and inflammation; mAb: monoclonal antibody; MRGPRX2: mas-related G protein-coupled receptor member X2; MS: multiple sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SM: small-molecule

MRGPRX2 Inhibition for the Treatment of Atopic Skin Diseases

Validated Biology with Multi-Billion $ Potential

- MRGPX2 is a mast cell-specific G protein-coupled receptor (GPCR) that triggers robust mast cell activation
- Approved biologics are highly successful and effective in treating mast-cell driven diseases
- Dupixent® is approved in AD and CSU, among other indications, and generates >$15B in LTM sales[1]

Opportunity for Improvement

- Anti-IgE (e.g., Xolair®) and anti-IL-4R (e.g., Dupixent®) are not sufficient to address clinical need in CSU and/or AD (non-IgE mast cell pathology)
- KIT mAbs (e.g., barzolvolimab/ Celldex) address mast cell biology but at the cost of some safety/convenience
- MRGPRX2 represents a novel (and potentially safer) way to address mast cell contribution in these conditions
- Need for improved potency/PK relative to early entrants into the clinic

Program Status

- Expect FIH in 2026
- Great opportunity to establish preliminary efficacy in Ph1b study (e.g., CIndU)

1. Sanofi earnings releases

AD: atopic dermatitis; CIndU: chronic inducible urticaria; CSU: chronic spontaneous urticaria; FIH: first-in-human; IgE: immunoglobin E; KIT: tyrosine kinase receptor for stem cell factor SCF; mAb: monocolonal antibody; MRGPRX2: mas-related G protein-coupled receptor member X2; PK: pharmacokinetics

Key Criteria Expected to Enable an MRGPRX2 Antagonist to be Best-in-Class

Potency

- We perform stringent evaluation of potency under physiologically relevant conditions
- Molecules that can block 90%+ of the effects of MRGPRX2 activators at double-digit nM concentrations (see below for AB102)

MAST CELL (LAD2) DEGRANULATION (CD107A) IN 100% HUMAN SERUM



Selectivity / Safety

- Exploratory safety studies completed in 3 species
- Competitor molecules have reported safety signals that may not support continued development
- Ongoing GLP studies progressing on schedule with AB102
- Additional molecules continue to be profiled

Human PK

- Based on the predicted human PK for our leading molecule, it could achieve clinically relevant exposures at 1/30 the exposures shown by the leading competitor

MODELED STEADY-STATE HUMAN PK



GLP: Good Laboratory Practice; IC: inhibitory concentration; LAD2: leukocyte adhesion deficiency type II; MRGPRX2: mas-related G protein-coupled receptor member X2; ng/mL: nanograms per milliliter; nM: nanometer; PK: pharmacokinetics

Conclusions

Multiple Upcoming Potential Catalysts

TIMING	STUDY	PRODUCT	EVENT
Early 2026	ARC-20	Casdatifan	• Additional analysis of the cas monotherapy cohorts in late-line ccRCC
Mid-2026	ARC-20	Casdatifan	• ORR and PFS data from the cas + cabo cohort in IO-experienced ccRCC
2026	Phase 1	MRGPRX2	• Initiation of first-in-human study
2H 2026	ARC-20 eVOLVE RCC02	Casdatifan	• Data from one or more of the early-line cohorts of ARC-20 and go / no go decision on the Phase 3 portion of eVOLVE-RCC02 • Target initiation of first phase 3 study for cas in an early-line setting of ccRCC
2026 (event-driven)	STAR-221	Domvanalimab	• Phase 3 data for dom + zim + chemo vs. nivo + chemo in 1L gastric cancer

1L: first-line; 2H: second half; BID: twice daily; cabo: cabozantinib; cas: casdatifan; ccRCC: clear cell renal cell carcinoma; chemo: chemotherapy; dom: domvanalimab; ESMO: European Society for Medical Oncology; mono: monotherapy; nivo: nivolumab; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; QD: once daily; zim: zimberelimab

ARCUS BIOSCIENCES

COMBINING TO CURE®